Low-Dose Aspirin Shows Promise in Reducing Colorectal Cancer Recurrence in Patients with PI3K Mutations

Who is this relevant for?

• Hospitals managing supply risk
• Distributors monitoring sourcing opportunities

The ALASCCA trial, enrolling over 3,500 patients across Sweden, Norway, Denmark, and Finland, has provided one of the first randomized confirmations that aspirin can cut colorectal cancer recurrence after surgery—but only in a genetically defined subgroup.

Patients with mutations in the PI3K signaling pathway, present in about 37% of colorectal tumors, saw recurrence rates drop from 14.1% to 7.7% with daily 160 mg aspirin versus placebo. For related genetic alterations, the reduction was from 16.8% to 7.7%. That is roughly a 50% reduction in risk.

The study tracked three years of disease-free survival. Among aspirin-treated patients with the relevant mutations, close to 89% remained cancer-free, compared to 79–81% in the placebo group. But the benefit came with higher severe side effects: 16.8% versus 11.6%.

For hospital procurement teams, the operational shift is twofold. First, the findings increase the likelihood that genetic testing for PI3K mutations will become standard for colorectal cancer patients after surgery. That means hospitals may need to expand in-house testing capacity or contract with reference labs. Second, it creates a new, steady demand for low-dose aspirin (160 mg) as a prescribed adjuvant therapy for a defined patient population.

Aspirin is inexpensive and globally available, but the precision medicine context changes its supply profile. Hospitals must ensure consistent sourcing of the correct dose and formulation—enteric-coated or not—and include it in post-surgery care pathways. Distributors may see an uptick in orders for low-dose aspirin from oncology departments, particularly in systems implementing universal genomic screening.

The trial results do not yet represent a standard of care. Guidelines will need to be updated, and questions about the optimal duration, dose, and patient selection remain. But the evidence is strong enough that procurement and supply chain managers in hospitals with colorectal surgery programs should be watching the development closely. Genetic testing infrastructure and aspirin inventory planning are the two operational levers to prepare.